Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	35.44	11.36	55.74	32.59	9.5
Short-Term Investments	0.05	46.52	2.62	8.98	44.84
Cash & Cash Equivalents	35.49	57.88	58.36	41.56	54.33
Cash Growth	-38.67%	-0.83%	40.41%	-23.50%	76.74%
Receivables	0.75	0.3	50.84	0	0.32
Other Current Assets	2.2	1.83	2.35	2.43	2.86
Total Current Assets	38.44	60	111.55	44	57.52
Property, Plant & Equipment	4.77	5.67	4.87	5.63	8.18
Goodwill and Intangibles	57.23	57.36	57.49	57.7	58.92
Other Long-Term Assets	0.58	0.63	0.63	0.62	0.86
Total Long-Term Assets	62.58	63.66	63	63.95	67.96
Total Assets	101.02	123.66	174.55	107.95	125.48
Accounts Payable	6.27	8.61	27.97	6.81	5.23
Deferred Revenue	29.5	37.15	50.57	0.19	0.25
Current Debt	0.88	0.95	0.83	0.76	1.22
Other Current Liabilities	-18.69	-27.73	-32.26	0	-0.2
Total Current Liabilities	17.96	18.98	47.12	7.77	6.49
Long-Term Debt	2.07	2.94	1.97	2.54	3.95
Other Long-Term Liabilities	18.97	29.8	34.56	2.51	3.79
Total Long-Term Liabilities	21.04	32.75	36.53	5.05	7.74
Total Liabilities	39	51.73	83.65	12.82	14.23
Total Debt	2.95	3.9	2.8	3.3	5.17
Debt Growth	-24.23%	39.04%	-15.14%	-36.11%	128.17%
Retained Earnings	-384.86	-363.37	-337.1	-294.08	-273.42
Comprehensive Income	-3.07	-3.57	-5.21	-3.67	-0.68
Shareholders' Equity	63.42	73.34	92.22	96.2	112.96
Net Cash / Debt	32.54	53.98	55.56	38.26	49.16
Net Cash / Debt Growth	-39.72%	-2.84%	45.21%	-22.18%	72.65%
Net Cash Per Share	0.19	0.32	0.34	0.25	0.34
Working Capital	20.48	41.02	64.43	36.23	51.03
Book Value Per Share	0.37	0.43	0.56	0.64	0.78

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).